Loading...
•
Sep 30
Phibro Q1 2026 Earnings Report
Phibro reported strong first quarter results for fiscal year 2026, with significant increases in net sales, net income, and adjusted diluted EPS, driven primarily by robust performance in its Animal Health segment.
Key Takeaways
Phibro Animal Health Corporation delivered an outstanding start to fiscal year 2026, with net sales surging 40% to $363.9 million and adjusted diluted EPS doubling to $0.73. The Animal Health segment was the primary growth engine, increasing 55% due to strong demand for MFAs, nutritional specialties, and vaccines. The company also raised its fiscal year 2026 Adjusted EBITDA guidance.
Net sales increased by 40% to $363.9 million, compared to the same period last year.
Net income rose by $19.6 million to $26.5 million, and diluted EPS increased by $0.48 to $0.65.
Adjusted EBITDA grew by $31.2 million to $61.9 million, reflecting strong operational performance.
The Animal Health segment's net sales increased by 55% to $283.5 million, driven by strong demand across its product categories.
Phibro
Phibro
Phibro Revenue by Segment
Revenue by Segment
Animal Health Revenue
CapyFin.comMFAs and other Revenue
CapyFin.comNutritional specialties Revenue
CapyFin.comVaccines Revenue
CapyFin.comMineral Nutrition Revenue
CapyFin.comPerformance Products Revenue
CapyFin.com Forward Guidance
Phibro has updated its financial guidance for fiscal year 2026, raising Adjusted EBITDA expectations while maintaining net sales guidance, reflecting confidence in continued growth and operational performance.
Positive Outlook
- Net sales are projected to be between $1.43 billion and $1.48 billion, representing 12% growth.
- Net income is expected to be between $75 million and $85 million, indicating 66% growth.
- Diluted EPS is guided to be between $1.83 and $2.08, a 65% increase.
- Adjusted EBITDA guidance has been raised to $230 million to $240 million, reflecting 28% growth.
- Adjusted diluted EPS is expected to be between $2.64 and $2.81, a 31% increase.
Challenges Ahead
- Guidance for GAAP measures assumes no additional foreign exchange (gains) losses for the year ending June 30, 2026, which could introduce variability.
- The company is not providing a reconciliation of forward-looking non-GAAP financial measures to GAAP due to uncertainty and potential variability, making direct comparison difficult.
- Future GAAP results may be materially impacted by uncertain factors not included in the non-GAAP reconciliation.
- The updated guidance does not explicitly detail potential headwinds from increased input and distribution costs, which were noted in the current quarter.
- The impact of fluctuations in certain currencies relative to the U.S. dollar, such as the Argentine Peso and Israeli New Shekel, could continue to affect foreign currency losses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income